Human epidermal growth factor receptor 2 (HER2), epithelial cell adhesion molecule (EpCAM), and mesothelin (MSLN) antigens along with NK group 2 member D ligand (NKG2DL), MUC-1, and CD133 have been licensed for use in clinical trials (Table 2) because they are among the most overexpressed antigens in patients with CRC (107). This evidence concerns the gene ERBB2 and colorectal carcinoma.